Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 6Endocrine 1CNS 1

Conditions

Brain Neoplasms 1902Glioblastoma 1795Glioma 1127Central Nervous System Neoplasms 599Astrocytoma 593Neuroblastoma 552Gliosarcoma 465Oligodendroglioma 363Neoplasms 312Breast Neoplasms 273Medulloblastoma 272Carcinoma, Non-Small-Cell Lung 226Recurrence 199Sarcoma 183Neoplasm Metastasis 183Melanoma 181Meningioma 177Ependymoma 175Lung Neoplasms 157Lymphoma 133Osteosarcoma 126Meningeal Carcinomatosis 126Neurofibromatosis 1 114Wilms Tumor 111Ovarian Neoplasms 110Diffuse Intrinsic Pontine Glioma 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Rhabdomyosarcoma 100Lymphoma, Non-Hodgkin 96Burkitt Lymphoma 89

Interventions

spartalizumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hereditary leiomyomatosis and renal cell cancer × CNS × Clear all
NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Novartis

Phase 1 Terminated
40 enrolled
CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡